Welcome to the TEsticular CAncer Consortium (TECAC)

Testicular germ cell tumorTesticular germ cell tumor (TGCT) is the most common type of cancer in men ages 20-40. The number of cases identified in all men is increasing every year. Several striking features characterize the epidemiology of TGCT:

    - increasing incidence,
    - racial disparity in risk and
    - high familial relative risks.

However, knowledge of TGCT risk factors and causes lags far behind that of other malignancies. Please see our section on TGCT background for additional information. 

The TEsticular CAncer Consortium (TECAC) is comprised of several investigators around the world with the common aim to pool together resources of all genome-wide association studies (GWAS) to indentify new genetic markers of risk, further characterize the existing genomic regions with risk markers, examine potential maternal or parent-of-origin effects though case-parent triads and dyads and finally create a consortium that formalizes the existing research alliances.

We hope that the findings from our study will greatly add to our understanding of TGCT and its causes, and improve treatment and prevention of this type of cancer.

2022 TECAC Annual Meeting

Due to the Covid 19 Pandemic, we have not held in person meetings. As the world begins to open up, we will ruminate about when to re-convene our annual meeting in person. In the meantime, we will continue to meet virtually. We will inform you about plans to meet in 2022 in the near future.